Downloads
Feature Article: Building Process Control Into Chromatographic Purification Of Viruses, Part 1
By Denise Gavin and Pete Gagnon
Many viral products are currently under development, including retrovirus, adenovirus, adeno-associated virus (AAV), herpes virus, pox virus (vaccinia, fowl, canary), lentivirus (HIV-based), and measles (and other paramyxovirus), as well as alpha, rhabdo, influenza, polio, and reovirus. Whether live viral vaccines or viral vectors for human gene therapies, viral products present a multitude of manufacturing challenges that must be overcome to deliver a product that is consistently safe and effective. Chromatography methods have a number of inherent features that make them well suited to address such challenges.
Complementarity among the many separation mechanisms supports development of multistep procedures capable of excluding contaminants to virtually any degree required to satisfy a particular application. The ability to conduct separations in closed systems that can be sanitized supports aseptic processing. Automation options make it possible to minimize human contribution to overall process variation.
Reprinted with permission from BioProcess International 4(10):22-31 (November 2006) To access this content, Register or Sign In.
The content you requested is only available to registered users of Bioresearch Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
